Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes

Mahdi, Ali J., Gosrani, Deepan, Chakraborty, Mallinath, Rees, Alexandra, Conner, Christine, Wilson, Keith, Rayment, Rachel and Alvares, Caroline 2018. Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes. British Journal of Haematology 180 (4) , pp. 603-604. 10.1111/bjh.14417

Full text not available from this repository.

Abstract

Acute myeloid leukaemia (AML) presenting in pregnancy is a rare event. The dilemma faced by the mother, her family and the medical team encompasses a number of difficult and often confounding issues. Here we report the first case of successful molecularly targeted treatment using the hypomethylating agent azacitidine with the multi-kinase inhibitor sorafenib in a pregnant woman with refractory AML resulting in no major foetal morbidity or mortality. A 39-year-old women presented in the 9th week of her first pregnancy with lethargy, easy bruising, circulating blasts and a markedly abnormal haematological profile (haemoglobin 51 g/l, white cell count 2·2 × 109/l, neutrophils count 1 × 109/l, platelet count 34 × 109/l). Bone marrow examination confirmed high-risk myelodysplastic syndrome (refractory anaemia with excess blasts type 2) with normal karyotype and no detectable molecular abnormality by reverse transcription polymerase chain reaction.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley
ISSN:	0007-1048
Last Modified:	27 Apr 2022 10:30
URI:	https://orca.cardiff.ac.uk/id/eprint/148097

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item